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Calcineurin/NFAT signaling is active in endothelial
cells and is proposed to be an essential component
of the tumor angiogenic response. Here, we investi-
gated the role of endothelial calcineurin signaling
in vivo in physiological and pathological angiogen-
esis and tumor metastasis. We show that this
pathway is dispensable for retinal and tumor angio-
genesis, but it is implicated in vessel stabilization.
While ablation of endothelial calcineurin does not
affect the progression of primary tumors or tumor
cell extravasation, it does potentiate the outgrowth
of lung metastases. We identify Bmp2 as a down-
stream target of the calcineurin/NFAT pathway in
lung endothelium, potently inhibiting cancer cell
growth by stimulating differentiation. We reveal a
dual role of calcineurin/NFAT signaling in vascular
regression or stabilization and in the tissue-specific
production of an angiocrine factor restraining cancer
cell outgrowth. Our results suggest that, besides
targeting the immune system, post-transplantation
immunosuppressive therapy with calcineurin inhibi-
tors directly targets the endothelium, contributing
to aggressive cancer progression.
INTRODUCTION
The formation of new blood vessels, or angiogenesis, is a hall-
mark of many human cancers that supports tumor growth and
metastasis (De Palma et al., 2017). Signaling via vascular
endothelial growth factors (VEGFs) and their endothelial receptorCell Rep
This is an open access article undtyrosine kinases (VEGFRs) are essential for vessel growth and
remodeling. Blocking VEGF-A/VEGFR-2 interaction or down-
stream signaling pathways such as phosphoinositide 3-kinase
(PI3K), the mammalian target of rapamycin (mTOR), and Akt
interfere with angiogenesis and vascular maintenance in many
pathological and physiological situations (De Palma et al.,
2017; Graupera et al., 2008; Kerr et al., 2016). VEGFR-2 activa-
tion also triggers the Ca2+/phospholipase-C gamma cascade,
which activates the Ca2+-dependent serine/threonine phospha-
tase calcineurin. Calcineurin dephosphorylates the nuclear fac-
tor of activated T cells (NFAT), leading to its nuclear entry and
transcriptional activity. Among the 5 members of the NFAT fam-
ily, NFAT1–NFAT4 are regulated by calcineurin. They were first
described in T cells; however, it is now evident that they are ex-
pressed by numerous cell types and have awide range of cellular
functions (Mancini and Toker, 2009).
In vitro studies of the calcineurin/NFAT pathway suggested
that it is a key downstream mediator of VEGFA-VEGFR2 re-
sponses, such as endothelial cell (EC) migration and proliferation
(Minami et al., 2004; Schweighofer et al., 2009; Zaichuk et al.,
2004). However, the in vivo role of the calcineurin/NFAT signaling
pathway in the tumor vasculature is not fully understood. Studies
of Down syndrome critical region-1 (DSCR1), a direct target and
endogenous inhibitor of calcineurin/NFAT, showed that Dscr1
overexpression suppresses calcineurin signaling, inhibits tumor
angiogenesis, and prevents tumor growth (Baek et al., 2009).
Dscr1 germline deletion reduced tumor growth as a result of
overactive calcineurin signaling, leading to EC apoptosis (Ryeom
et al., 2008). In addition, Dscr1/ mice develop more lung me-
tastases due to the increased production of angiopoietin-2,
which promotes vascular permeability and facilitates tumor cell
extravasation (Minami et al., 2013).
Here, we directly investigated the role of calcineurin signaling in
tumor angiogenesis, growth, and metastasis, using a model withorts 26, 1227–1241, January 29, 2019 ª 2019 The Author(s). 1227
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Endothelial Calcineurin Signaling Controls Vessel Regression in the Postnatal Retina
(A) Scheme for tamoxifen injection and retina collection of pups.
(B) Representative images of a retina leaflet from Cnb1WT and Cnb1Dbec pups. Staining for collagen IV (green), Icam2 (red), and IB4 (blue).
(C) Vascular radial expansion is impaired in Cnb1Dbec retinas. ***p = 0.0001; n = 6 Cnb1WT; n = 6 Cnb1Dbec.
(D) Vessel density measured by IB4 is reduced in Cnb1Dbec retinas. *p = 0.0347; n = 6 Cnb1WT; n = 6 Cnb1Dbec.
(E) Representative images of empty sleeves from Cnb1WT and Cnb1Dbec retinas. Staining for Icam2 (green) and collagen IV (red). Arrowheads indicate empty
sleeves.
(F) The number of empty sleeves is increased in Cnb1Dbec retinas. Quantification of the number of Icam2, collagen IV+ area normalized to the total vascularized
area. *p = 0. 0273; n = 6 Cnb1WT; n = 6 Cnb1Dbec.
(G) Increased association of pericytes with empty collagen sleeves in Cnb1Dbec retina. Immunofluorescent staining for pericyte marker CD13 (gray), CD31 (green),
and collagen IV (red). Arrowheads indicate a CD13 empty sleeve in Cnb1WT and a CD13+ empty sleeve in Cnb1Dbec.
(H) Quantification of total pericyte coverage in Cnb1WT and Cnb1Dbec pups. n = 3 Cnb1WT; n = 3 Cnb1Dbec.
(legend continued on next page)
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inducible endothelial-specificablationofcalcineurin. Incontrast to
previous observations in vitro and in Dscr1 transgenic and
knockout mice, we observed that calcineurin is dispensable for
both physiological and pathological angiogenesis, but it contrib-
utes to vessel stabilization. Such decreased vascular stability
does not significantly affect primary tumor growth; however, loss
of endothelial calcineurin stimulates the outgrowth of lung metas-
tases by decreasing bone morphogenetic protein-2 (Bmp2) pro-
duction, thereby reducing cancer cell differentiation. Our data
reveal a dual role of calcineurin/NFAT signaling in the vasculature:
a general role as a fine-tuner of vessel stabilization and an organ-
specific role as a regulator of a paracrine factor that restrains
metastasis outgrowth. They also indicate that besides targeting
the immune system, post-transplantation immunosuppressive
therapywithcalcineurin inhibitorsdirectly targets theendothelium,
thereby contributing to aggressive cancer progression.
RESULTS
Endothelial Calcineurin Signaling Regulates Vessel
Regression in the Postnatal Retina
We investigated the role of calcineurin in physiological angiogen-
esis using the mouse postnatal retina model (Gerhardt et al.,
2003). Analysis of P5 retinas from mice with endothelial-specific
inactivation of the main calcineurin subunit Cnb1 (Cnb1Dbec) or
wild-type (Cnb1WT) (Figure 1A) demonstrated that Cnb1Dbec
retinal vascularization was decreased, as shown by a reduced
radial expansion and vessel density (Figures 1B–1D). However,
the loss of endothelial calcineurin had no impact on the
apoptosis and proliferation of ECs, as determined by staining
for caspase-3 and 5-ethynyl-20-deoxyuridine (EdU) incorpora-
tion (Figures S1A and S1B). No changes were observed in the
morphological appearance of the angiogenic front (Figure S1C)
or in arterial or venous branching from the main vessels (Figures
S1D and S1E) in Cnb1WT and Cnb1Dbec retinas.
We next analyzed whether the loss of calcineurin affects
vessel stabilization. Vessel maturation is characterized by an
increased deposition of basement membrane, pericyte recruit-
ment, and pruning of the excessive blood vasculature (Fruttiger,
2007; Korn and Augustin, 2015). Vessel regression is induced by
low-flow conditions to which ECs respond by retracting and
undergoing apoptosis or by migrating away and integrating
elsewhere in the vascular tree (Franco et al., 2015; Korn and Au-
gustin, 2015). In doing so, ECs leave behind collagen IV+ ‘‘empty
sleeves’’ (Baluk et al., 2003). The number of empty sleeves was
increased in Cnb1Dbec retina; however, there was no change in
the overall pericyte coverage, as determined by staining for the
pericyte marker CD13 (Armulik et al., 2011) (Figures 1E–1H).
Higher numbers of pericytes remained associated with the
empty sleeves of Cnb1Dbec retinas (Figures 1G, 1I, and 1J), indi-
cating that such pericytesmay survive better ormigrate less after
the retraction of calcineurin-deficient ECs. Our data indicate that(I) CD13 mean fluorescence intensity (MFI) is similar between Cnb1WT and Cnb1
(J) Cnb1Dbec retinas have an increased number of CD13+ pericytes in the empty
ns, not significant; error bars represent means ± SDs. Two-tailed Student’s t tes
Scale bars: (B) 200 mm, (E and G) 50 mm.calcineurin signaling does not contribute to sprouting angiogen-
esis, but rather is implicated in vessel stabilization.
Endothelial Calcineurin Signaling Is Dispensable for
Tumor Angiogenesis and Tumor Growth
To study the role of calcineurin in pathological angiogenesis, we
injected syngeneic melanoma B16F10 cells subcutaneously in
Cnb1WT and Cnb1Dbec mice (Figure 2A). The growth of primary
B16F10 tumors was minimally decreased in Cnb1Dbec animals,
and we observed similar results in the Lewis lung carcinoma
model (Figure 2B and data not shown). The quantification of tu-
mor volume over time and tumor weight after sacrifice showed a
non-significant tendency toward reduced primary tumor size in
Cnb1Dbec mice (Figures 2C and 2D). EGFP was uniformly high
in tumor ECs, indicating high activity of the Pdgfb-iCreERT2-
Ires-EGFP transgene (Claxton et al., 2008), and analysis of
sorted tumor ECs confirmed the significantly reduced expres-
sion of both Cnb1 and the calcineurin/NFAT target gene Dscr1
(Figures S2A–S2C). Further analysis of the tumor vasculature
did not reveal differences in vascular density or vessel pericyte
coverage between Cnb1WT and Cnb1Dbec tumors (Figures
2E–2H), indicating that calcineurin is dispensable for tumor
vessel expansion and maturation.
The loss of calcineurin increased the number of empty
sleeves in the retinal vasculature (Figure 1F); therefore,
we analyzed collagen IV distribution in B16F10 tumors. We
observed no change in the overall collagen IV staining (Figures
2I and 2J). However, when analyzing the avascular collagen IV,
we noticed an increase in the collagen IV+ empty sleeves in
Cnb1Dbec tumors (Figures 2I and 2K). Our results indicate that
similar to the retinal vasculature, calcineurin is dispensable
for the tumor angiogenic response but fine-tunes the tumor
vessel stability, and its inactivation has only a marginal impact
on primary tumor growth.
Calcineurin Deletion in the Endothelium Increases
Cancer Cell Metastasis in the Lung
To study the role of endothelial calcineurin in a metastatic
context, we injected intravenously (i.v.) B16F10 cells (Figure 3A).
We analyzed whether the early steps of metastasis are affected,
and 5 days after the i.v. injection, there was no detectable differ-
ence in the number of lung metastases between Cnb1WT and
Cnb1Dbec mice (Figures 3B and 3C). However, we observed
significantly more metastases in Cnb1Dbec lungs compared to
wild-type lungs 12 days after cancer cell injection (Figures 3D
and 3E). The increased metastasis in Cnb1Dbec lungs was also
apparent at 19 days post-injection (Figures 3F and 3G), but the
difference between the 2 genotypes was less prominent. Simi-
larly, i.v.-injected MC38-GFP colorectal cancer cells generated
significantly more metastases in Cnb1Dbec mice (Figures S3A
and S3B). Our results thus indicate that endothelial calcineurin
signaling restrains the growth of lung metastasis.Dbec pups. n = 3 Cnb1WT; n = 3 Cnb1Dbec.
sleeves area. *p = 0.0346; n = 3 Cnb1WT; n = 3 Cnb1Dbec.
t was performed on all of the data represented.
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Figure 2. Endothelial Calcineurin Signaling Does Not Affect Primary Tumor Growth and Angiogenesis
(A) Scheme for tamoxifen and subcutaneous B16F10-luc cell injections.
(B) Representative pictures of tumors ex vivo from Cnb1WT and Cnb1Dbec mice.
(C) Tumor growth is not affected in Cnb1Dbec mice; n = 4 per genotype.
(D) Tumor weight is not affected in Cnb1Dbec mice; n = 4 per genotype.
(E) Comparable primary tumor blood vascular density in Cnb1WT and Cnb1Dbec mice. Staining for Vegfr2 (red) and DNA (blue) of primary tumors.
(F) Quantification of the blood vessel density in Cnb1WT and Cnb1Dbec tumors. Vegfr2 area was normalized to the total DAPI area and plotted relative to wild-type
(WT); n = 5 per genotype.
(G) Representative images of pericytes in Cnb1WT and Cnb1Dbec B16F10 primary tumors. Staining for NG2 (red), CD31 (green), and DNA (blue).
(H) Pericyte (NG2) area normalized to the CD31 area is comparable in Cnb1WT and Cnb1Dbec tumors; n = 4 per genotype.
(I) More avascular collagen IV is present in Cnb1WT tumors compared to Cnb1Dbec tumors. Immunofluorescent staining for collagen IV (red) and CD31 (green) in
Cnb1WT and Cnb1Dbec tumors. Arrowheads indicate empty sleeves.
(legend continued on next page)
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Immune cells are major players in metastasis initiation and
progression. Natural killer (NK) cells and Cd8+ T cells can
eradicate metastatic cancer cells, whereas macrophages and
neutrophils enhance metastasis formation (Kitamura et al.,
2015). Therefore, we analyzed major immune cell populations
in Cnb1WT and Cnb1Dbec lungs after i.v. injection of B16F10 cells.
We did not observe significant changes in B cells, neutrophils,
monocytes and macrophages, or NK cells between Cnb1WT
and Cnb1Dbec mice. Although there was some increase in naive
T cell infiltration in Cnb1Dbec animals, this did not translate into
significant changes in activated and memory T cells (Figures
S4A–S4G). Thus, the increased metastasis phenotype observed
in Cnb1Dbec mice is likely not initiated by immune cells.
Calcineurin Deletion in the Endothelium Increases the
Outgrowth Potential of Cancer Cells in Lungs
To evaluate whether calcineurin affects the survival of cancer
cells in the circulation or their extravasation, we analyzed the
fate of fluorescently labeled B16F10 cells in the lungs 24 h after
i.v. injection. A similar number of cancer cells were present in the
lungs of wild-type and Cnb1Dbec mice (Figures S4H and S4I).
Thus, endothelial calcineurin/NFAT signaling does not play a
major role in early metastatic dissemination.
To study whether this pathway affects the outgrowth of
cancer cells in the lung microenvironment, we injected Cnb1WT
and Cnb1Dbec mice i.v. with B16F10 cells first and deleted cal-
cineurin 5 days later (Figure 4A), when micrometastases were
already established. Mice were sacrificed 12 days after tumor
cell injection, and thus 7 days after calcineurin inactivation.
As expected, there was no difference in the total number of
metastatic foci between Cnb1WT and Cnb1Dbec. However, we
observed a significantly increased number of large colonies
(>0.5 mm) in Cnb1Dbec lungs compared to Cnb1WT lungs (Fig-
ures 4B–4D), indicating that endothelial calcineurin restrains
metastatic outgrowth.
The largest difference in metastatic foci was observed at
day 12 (Figures 3D and 3E), but it was reduced at a later stage
(Figures 3F and 3G). These results suggest that calcineurin
is important during the initial metastatic outgrowth, but
contributes less after metastatic lesions have reached a
certain size. To study this question, we induced calcineurin
deletion 9 days after the i.v. injection of cancer cells (Figure 4E),
and the metastases were quantified at day 16. In this setting,
we did not observe changes in the number or size of the
metastatic foci between Cnb1WT and Cnb1Dbec mice (Figures
4F–4H). We thus conclude that the endothelium of Cnb1Dbec
mice promotes the outgrowth of cancer cells during a restricted
period.
The increased outgrowth at early stages could be due to the
fact that in macrometastases, proportionally fewer tumor cells
are located in the vicinity of blood vessels (Figure S5A). The
growth of cancer cells in macrometastases thus may be less(J) Overall collagen IV staining in Cnb1WT and Cnb1Dbec tumors is unchanged; n
(K) Avascular collagen IV is increased in Cnb1Dbec tumors compared to WT tumo
plotted relative to WT. *p = 0.0399; n = 5 Cnb1WT; n = 4 Cnb1Dbec.
ns, not significant; error bars represent means ± SDs. Two-tailed Student’s t tes
Scale bars: (B) 1 mm, (E) 50 mm, (G and I) 100 mm.sensitive to the endothelial-derived paracrine factors. We evalu-
ated whether calcineurin loss affects the proliferation of cancer
cells in macrometastases by analyzing EdU incorporation. We
did not observe any differences in the proliferation of cancer cells
in macroscopic lesions of Cnb1WT or Cnb1Dbec lungs when
analyzing lungs 19 days post-injection of cancer cells (Figures
S5B and S5C). However, in the 12-day outgrowth experiments,
we observed an increase in the EdU+ metastatic area in
Cnb1Dbec lungs compared to wild-type lungs (Figures 5A
and 5B). Further analysis using GFP-labeled B16F10 cells
confirmed the increased proliferation of cancer cells 12 days
post-injection in Cnb1DDbec lungs (Figures 5C and 5D). We also
evaluated whether endothelial NFAT signaling is influenced by
the presence of metastasis and whether such activation is organ
specific. The expression of the direct NFAT target gene Dscr1
was not affected in the lung endothelium by the presence of
cancer cells (Figure S5D). However, we observed that the basal
level of NFAT signaling in the lung ECs was significantly higher in
comparison to ECs from the gut and skin (Figure S5E). Our data
thus reveal tissue-specific differences in the levels of endothelial
calcineurin activation and show that its loss promotes the
proliferation of lung micrometastases.
Calcineurin Signaling Regulates Bmp2 Expression in
Lung Endothelial Cells
To mechanistically unravel the contribution of endothelial calci-
neurin signaling to cancer cell outgrowth, we transduced human
umbilical vein ECs (HUVECs) with lentiviruses encoding a
constitutively active form of NFATc1 (caNFATc1). The mutation
of serines in the SRR and SPXX repeat motifs of the NFATc1
regulatory domain prevents the phosphorylation of NFATc1
and imposes its nuclear localization (Monticelli and Rao,
2002). As expected, HUVECs transduced with caNFATc1 had
increased nuclear NFATc1 levels compared to GFP controls
(Figures S6A and S6B). Similarly, a lower-motility NFATc1
band was observed in lysates from caNFATc1-HUVECs, con-
firming the loss of phosphorylation (Figure S6C). There was a
10-fold upregulation of the NFAT target DSCR1 in caNFATc1-
HUVECs, thereby confirming the overactivation of NFAT
signaling (Figure 6A). To identify potential paracrine factors
that affect metastatic outgrowth, we analyzed the expression
of cell surface or secreted molecules that were previously
shown to be regulated in HUVECs by calcineurin/NFAT (Suehiro
et al., 2014; Figure S6D). We observed a significantly increased
expression of Tissue Factor and BMP2, but not of other
target genes such as VCAM1, ANG2, or ESELECTIN or another
member of the BMP family, BMP4 (Figure 6A).
To study whether the target genes identified by our in vitro
analyses are also regulated by calcineurin signaling in vivo, we
sorted lung blood ECs from wild-type and Cnb1Dbec mice i.v.
injected with B16F10 cells (Figures S6E–S6H). As expected,
we observed a strong decrease in Cnb1 in ECs from Cnb1Dbec= 5 Cnb1WT; n = 4 Cnb1Dbec.
rs. Quantification of the avascular (CD31) collagen IV area or empty sleeves,
t was performed on all of the data represented.
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Figure 3. Endothelial Calcineurin Signaling Restrains Lung Metastasis
(A) Scheme for tamoxifen and B16F10 cell injections.
(B) Representative images of lungs 5 days after B16F10 i.v. injection.
(C) The number of B16F10 colonies in lungs is not affected in Cnb1Dbec mice 5 days after i.v. injection; n = 7 per genotype. Data combined from 2 independent
experiments.
(D) Representative images of lungs 12 days after B16F10 i.v. injection.
(E) Cnb1Dbec lungs have more B16F10 colonies 12 days after tumor cell injection. **p = 0.0066; n = 9 per genotype. Data combined from 2 independent
experiments.
(F) Representative images of Cnb1Dbec and Cnb1WT lungs 19 days after B16F10 i.v. injection.
(G) Cnb1Dbec lungs have more B16F10 colonies 19 days after tumor cell injection. *p = 0.0212; n = 3 Cnb1WT; n = 5 Cnb1Dbec.
ns, not significant; error bars represent means ± SDs. Two-tailed Student’s t test was performed on all of the data represented.
Scale bars: (B, D, and F) 1 mm.
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Figure 4. Endothelial Calcineurin Deletion Increases the Outgrowth of Metastatic Cancer Cells
(A) Scheme for tamoxifen and intravenous (i.v.) B16F10 injection for early outgrowth experiments.
(B) Cnb1Dbec lungs have significantly larger (>0.5 mm) colonies compared to Cnb1WT lungs 12 days after i.v. injection and tamoxifen administration at day 5.
**p = 0.0037; n = 4 Cnb1WT; n = 5 Cnb1Dbec.
(C) Representative pictures of lungs from Cnb1WT and Cnb1Dbec mice from the 12-day outgrowth experiment.
(D) The number of lung B16F10 colonies is not affected in Cnb1Dbec mice 12 days after i.v. injection and tamoxifen administration at day 5; n = 4 Cnb1WT; n = 5
Cnb1Dbec.
(E) Scheme for tamoxifen and intravenous B16F10 injections for late outgrowth experiments.
(F) Similar size B16F10 colonies are present in Cnb1WT and Cnb1Dbec lungs 16 days after i.v. injection and tamoxifen administration at day 9; n = 5 Cnb1WT; n = 4
Cnb1Dbec.
(G) Representative pictures of Cnb1WT and Cnb1Dbec lungs from the 16-day outgrowth experiment.
(H) The number of lung B16F10 colonies is not affected in Cnb1Dbec mice 16 days after i.v. injection and tamoxifen administration at day 9; n = 5 Cnb1WT; n = 4
Cnb1Dbec.
ns, not significant; error bars represent means ± SDs. Two-tailed Student’s t test was performed on all of the data represented.
Scale bars: (C and G) 1 mm.
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Figure 5. Endothelial Calcineurin Signaling Restricts the Proliferation of Micrometastases in the Lung
(A) Representative images of lung sections from the short-term (day 12) metastasis outgrowth experiment, stained for EdU (white) and for DAPI (blue).
(B) Proliferation is increased in Cnb1Dbec lungs injected for 12 days with B16F10 and with tamoxifen injection at day 5. *p = 0.0110; n = 4 Cnb1WT; n = 5 Cnb1Dbec.
(C) Representative images of B16F10-GFP metastasis in Cnb1WT and Cnb1Dbec lungs. Immunofluorescent staining for DNA (blue), EdU (red), and GFP (green).
(D) Quantification of tumor cell proliferation in Cnb1Dbec andWT lungs 12 days after tumor cell injection. *p = 0.0329; n = 5 Cnb1WT; n = 5 Cnb1Dbec. The EdU+ area
was normalized to the GFP+ area.
ns, not significant; error bars represent means ± SDs. Two-tailed Student’s t test was performed on all of the data represented.
Scale bars: (A) 1 mm, (C) 100 mm.mice (Figure 6B). Calcineurin inactivation significantly decreased
the endothelial expression of Bmp2, while the expression of
other previously published target genes such as TissueF,
Angpt2, or Thbs1 was not modified (Figure 6B).
Bmp2 Inhibits Tumor Cell Growth in 3D
Lung BMP signaling maintains cancer cells in a dormant state by
preventing their self-renewal (Gao et al., 2012). Based on this
finding and our own observations, we selected BMP2 as
a potentially important calcineurin target during tumor progres-
sion. BMP2 treatment strongly activated Smad-1/5 phos-
phorylation in B16F10 cells (Figure 6C), which was inhibited by1234 Cell Reports 26, 1227–1241, January 29, 2019dorsomorphin homolog 1 (DMH1), a small molecule antagonist
targeting the activation of BMP type I receptors (Hao et al.,
2010). However, BMP2 did not affect melanoma cell growth in
a 2-dimensional (2D) monolayer (Figure 6D). As metastases
grow in a 3D environment, we studied whether BMP2 affects
the ability of B16F10-luc cells, tagged with firefly luciferase to
form spheroids in Matrigel. In 3D conditions, the addition of
BMP2 significantly decreased luciferase signal and spheroid
growth (Figures 6E–6G). BMP2 treatment significantly reduced
the number of large 3D colonies, whereas the number of small
colonies was increased, indicating that BMP signaling inhibits
spheroid outgrowth (Figure 6G). The inhibition of spheroid
Figure 6. Calcineurin Regulates Bmp2 Expression in the Endothelium, a Potent Inhibitor of Tumor Cell Growth
(A) caNFATc1 induces the expression of DSRC1, BMP2, and TISSUEF in HUVECs. The qRT-PCR analyses of the indicated genes; n = 3, **p = 0.0091 DSCR1,
*p = 0.0257 BMP2, and *p = 0.0318 TISSUEF.
(B) Loss of calcineurin reduces the expression of Cnb1, Dscr1, and Bmp2 in the BEC-2 population of lung ECs. *p = 0.0316, **p = 0.0029; n = 3 Cnb1WT-GFP; n = 4
Cnb1Dbec.
(C) BMP2 induces the phosphorylation of Smad-1/5 in B16F10 cells. Cells were treated with 100 ng/mL BMP2 in the presence or absence of 1 or 3 mM DMH1.
Western blot for the indicated proteins.
(D) BMP2 does not affect B16F10 cell growth in 2D. Cells were treated with vehicle or 100 ng/mL BMP2 for 24 and 48 h and analyzed by CyQuant DNA-based
assay.
(E) BMP2 reduces B16F10 cell growth in 3D. Representative images of B16F10 spheroids treated with 100 ng/mL BMP2, BMP2 + 3 mM DMH1, or vehicle.
(legend continued on next page)
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expansion by BMP2 was rescued by the combined treatment
with DMH1 (Figures 6E, 6H, and 6I). Similar to B16F10 cells,
BMP2 treatment activated Smad-1/5 signaling and reduced
the 3D growth of MC38 cells, which was rescued by DMH1 (Fig-
ures S7A–S7C).
BMP2 Signaling Promotes Melanoma Cell
Differentiation
To further evaluate the pathways affected by BMP2 inmelanoma
cells, we compared the transcriptomes of control and BMP2-
treated B16F10 3D spheroids. The expression of 54 and 72
genes was significantly up- or downregulated in response to
BMP2 (false discovery rate [FDR] <0.05, fold change [FC] >2).
As expected, BMP2 target genes ID2, SMAD6, and ATOH8
were significantly induced (Figure 7A; Koch et al., 2016). BMP2
strongly repressed the nuclear factor kB (NF-kB) pathway, previ-
ously implicated in melanoma cell survival, invasion, and metas-
tasis (Figure 7B; Amiri and Richmond, 2005). In agreement with
reduced spheroid growth, BMP2 downregulated the expression
of genes involved in mitosis, targets of CMYC and E2F transcrip-
tion factors, and genes associated with the mTOR complex 1
pathway (Figure 7B). BMP2 treatment also repressed gene sig-
natures associated with hypoxia and glycolysis and oxidative
phosphorylation, indicating overall reduced metabolic activity
(Figure 7B). We observed significantly increased expression of
genes important for melanogenesis, such as Serpin F1, TYR,
GPR143, Mlph, SLC45a2, and MITF (Figure 7A; Chen et al.,
2016; Ferna´ndez-Barral et al., 2014; Kondo and Hearing,
2011). Analysis of Gene Ontology (GO) terms for biological pro-
cesses revealed that 5 of 9 GO terms related to pigmentation
and melanogenesis were significantly induced in BMP2-
treated melanoma cells, indicating increased differentiation
(Figure 7C; Table S1). Human melanomas can be categorized
into 4 progressive subtypes along a differentiation trajectory
that resembles different stages of melanocyte embryonic devel-
opment (Tsoi et al., 2018). The BMP2-dependent transcriptional
signature of B16F10 cells correlated best with a highly differen-
tiated humanmelanocytic subtype, followed by transitory, neural
crest-like, and undifferentiated subtypes (Figure 7D). These data
validate the pro-differentiation effect of BMP2 inmelanoma cells.
We evaluated the differentiation of B16F10metastases in vivo by
staining for levodopa (L-DOPA) as a readout for tyrosinase activ-
ity and melanin biosynthesis (Lanza et al., 2017). We confirmed
that upon calcineurin deletion, and thus reduced BMP2 expres-
sion, lung metastases had reduced tyrosinase activity (Figures
7E and 7F). Our data indicate that BMP2 signaling inhibits
the 3D growth of cancer cells by promoting differentiation along
melanocytic lineage and reducing metabolic activity and cell-
cycle progression.(F) Quantification of B16F10-luc spheroid growth. Bioluminescence was quantifi
(G) BMP2 treatment reduces B16F10 spheroid expansion. Quantification of the
(>200 mm). *p = 0.0157; **p = 0.0019; ***p = 0.0002; n = 3 per treatment conditio
(H) DMH1 rescues the decreased B16F10-luc spheroid formation by BMP2. Biolum
DMH1.
(I) DMH1 treatment reduces the number of B1610 small spheroids and increas
**p = 0.0027, ***p = 0.0006; n = 3 per treatment condition.
Error bars represent means ± SDs. Two-tailed Student’s t test was performed on
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To study the role of endothelial-derived BMP2 in vivo we
generated Bmp2flox/flox; Pdgfb-iCreERT2 mice (Bmp2Dbec) and
analyzed retinal angiogenesis and metastatic colonization. In
postnatal retina, vascular density but not radial expansion was
significantly reduced upon endothelial inactivation of BMP2,
and there was a tendency toward an increased number of
collagen IV+ empty sleeves (Figures 7G–7J). Most important, in
lung colonization experiments, we observed that the loss of
endothelial BMP2 enhanced the formation of metastases (Fig-
ures 7K and 7L). The effect of endothelial Bmp2 loss on meta-
stastic outgrowth was less pronounced compared to calcineurin
inactivation (Figures 3D and 3E). These in vivo results indicate
that BMP2 is an important effector molecule acting downstream
of calcineurin in ECs, although additional calcineurin targets are
also likely involved.
DISCUSSION
In this work, we used an EC-specific calcineurin deletion model
to investigate the role of this signaling pathway in physiological
and pathological angiogenesis and tumor metastasis. We report
that angiogenic sprouting and primary tumor growth are not
significantly affected by the absence of calcineurin in ECs.
However, both in physiological and pathological situations,
calcineurin modulates vascular regression. Most important, our
study shows that the ablation of calcineurin in the endothelium
promotes metastatic outgrowth.
Earlier work suggested that calcineurin has an essential role in
sprouting angiogenesis in vitro and in vivo (Herna´ndez et al.,
2001; Mena et al., 2014). However, during embryogenesis, calci-
neurin is crucial for the formation of heart valves and coronary
vessels and for the maturation of lymphatic vessels, but it is
dispensable for the growth of other vascular beds (Bushdid
et al., 2003; de la Pompa et al., 1998; Norrme´n et al., 2009;
Sabine et al., 2012; Zeini et al., 2009). Here, in a model of phys-
iological retinal angiogenesis, we show that calcineurin is
dispensable for EC proliferation and sprouting. In contrast,
vessel regression was affected, indicating that endothelial calci-
neurin signaling is involved in vessel stabilization and remodel-
ing. In addition to the VEGF-A/VEGFR2 pathway, calcineurin
acts downstream of the non-canonical Wnt pathway in several
cell types, including blood ECs (De, 2011; Scholz et al., 2016),
and defective vessel stabilization was observed in models with
an EC-specific ablation of non-canonical WNT signaling compo-
nents (Franco et al., 2016; Korn et al., 2014; Scholz et al., 2016).
Loss of endothelial calcineurin also leads to increased pericyte
association with empty sleeves, indicating that this pathwayed by Xenogen imaging. **p = 0.0066; n = 5 Ctrl; n = 3 BMP2.
number of small (50–100 mm), intermediate (100–200 mm), and large colonies
n.
inescence was quantified by Xenogen imaging. *p = 0.0366; n = 3 BMP2, n = 3
es the number of larger spheroids (>400 mm) compared to BMP2 treatment.
all of the data represented. Scale bars: (E) 200 mm, (F and H) 2 mm.
Figure 7. BMP2 Regulates the Growth and Differentiation of Melanoma Cells and Retinal Angiogenesis
(A) Heatmap of BMP2 targets and melanogenesis-related genes induced by BMP2 in B16F10 cells.
(B) Gene set enrichment analysis (GSEA) waterfall plot for the hallmark gene sets significantly affected by BMP2 in B16F10 3D spheroids; upregulated (pink) and
downregulated (blue) pathways with adjusted p < 0.05.
(C) GO biological processes ‘‘Pigmentation’’ and ‘‘Response to Bmp’’ are significantly enriched in BMP2-treated B16F10 spheroids.
(D) Signature of BMP2-treated B16F10 spheroids is enriched in human differentiated melanomas.
(E) Representative pictures of L-DOPA staining in Cnb1WT and Cnb1Dbec lungs 12 days post-i.v. injection.
(F) Tyrosinase activity is reduced in B16F10 metastases in Cnb1Dbec lungs 12 days post-i.v. injection; n = 5 Cnb1WT; n = 5 Cnb1Dbec.
(G) Representative images of a P5 retina leaflet from BMP2WT or BMP2Dbec mice, staining for CD31 (green).
(H) Reduced vascular density in P5 BMP2Dbec retina. ***p = 0.0008, n = 6 BMP2WT; n = 8 BMP2Dbec.
(I) Radial expansion is similar in BMP2WT and BMP2Dbec retinas; n = 4 BMP2WT; n = 6 BMP2Dbec.
(legend continued on next page)
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regulates mural cell behavior. It is not yet clear whether pericytes
from remodeling vessels remain in the empty sleeves and un-
dergo apoptosis or migrate onto the surviving vessel (Korn and
Augustin, 2015). Our findings indicate that pericytes remain in
the empty sleeves and that upon calcineurin deletion, these peri-
cytes would have better survival rates.
Pharmacological calcineurin inhibition decreased tumor
angiogenesis and tumor growth in several studies (Courtwright
et al., 2009; Medyouf et al., 2007). However, in our model,
despite the efficient deletion of Cnb1 and the inhibition of calci-
neurin/NFAT signaling in the tumor endothelium, vascular den-
sity was not significantly affected, whereas vascular stabilization
was decreased. The tumor phenotype of Cnb1Dbec mice is thus
also rather similar to that of mice with deficient endothelial
non-canonical WNT signaling, in which a defective vessel stabi-
lization and only a minor effect on primary tumor growth have
been reported (Scholz et al., 2016). It is conceivable that the
pharmacological inhibition of calcineurin blunts tumor growth
in cancers, in which calcineurin/NFAT drives malignant cell pro-
liferation, such as in T and B cell lymphomas (Medyouf et al.,
2007), or alternatively, when the tumor vasculature is especially
sensitive to the loss of non-canonical WNT signaling.
A more intriguing part of our study was that endothelial calci-
neurin restricts the outgrowth of metastases. This may explain in
part the clinical observations that solid organ transplant recipi-
ents are both more susceptible to develop de novo cancer and
have a more aggressive course of the disease in comparison
to the general population (Chapman et al., 2013; Sherston
et al., 2014). Studies of Dscr1/ mice with hyperactive NFAT
signaling proposed that the increased production of endothelial
Ang2 drives cancer cell extravasation by increasing lung
vascular permeability (Minami et al., 2013). In contrast, in mice
with endothelial calcineurin inactivation, we did not observe sig-
nificant changes in endothelial Angpt2 expression or metastatic
cancer cell behavior up to 12 days after intravenous injection,
which argues against the importance of calcineurin during the
early stages of metastasis. Rather, we observed an increased
outgrowth of metastatic colonies in Cnb1Dbec mice during a
critical time window, after which metastatic growth becomes
independent of endothelium-derived paracrine signals.
Mechanistically, we propose that intact calcineurin signaling in
lung ECs induces the expression of BMP2, which restrains the
outgrowth of micrometastases by promoting cell differentiation.
Calcineurin activation induces BMP2 in ECs in vitro and in vivo,
and BMP2 treatment potently suppresses the 3D growth of can-
cer cells. Furthermore, the analyses of melanoma cell transcrip-
tomes revealed that together with reducing metabolic activity
and cell-cycle progression, BMP2 directed differentiation along
the melanocytic lineage. In addition, metastases in Cnb1Dbec
lungshad lower tyrosinaseactivity, confirming the reduceddiffer-
entiation of B16F10 cells when Bmp2 expression downstream of(J) Quantification of empty sleeves in BMP2WT and BMP2Dbec retinas. The numb
n = 6 BMP2WT; n = 8 BMP2Dbec.
(K) Representative images of Bmp2WT and Bmp2Dbec lungs 12 days after B16F1
(L) Quantification of lung metastases in Bmp2WT and Bmp2Dbec 12 days post-i.v. i
independent experiments.
Error bars represent means ± SDs. Two-tailed Student’s t test was performed on
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of endothelial Bmp2 increased themetastatic potential of cancer
cells, although to a lesser extent than calcineurin deletion.
We have not confirmed whether endothelial Bmp2 deletion
directly affects the differentiation of B16F10 in vivo. However,
comparison of the BMP2-dependent transcriptional signature
ofB16F10cellswith humanmelanomas (Tsoi et al., 2018) showed
that it correlates best with a melanocytic differentiated subtype.
Calcineurin activates all 4 NFAT isoforms (Mancini and Toker,
2009), and previous studies suggested the roles both for NFATc1
and NFATc3 in vascular remodeling and angiogenesis (Bushdid
et al., 2003; Scholz et al., 2016). The question of which NFAT
isoform relays calcineurin activation in the endothelium during
metastatic outgrowth thus merits future investigation.
From the clinical point of view, the use of calcineurin inhibitors
for immunosuppressive therapy in solid organ transplant recipi-
ents is strongly associated with increased de novomalignancies,
including melanomas, and especially with a more aggressive
course of disease (Chapman et al., 2013; Sherston et al., 2014;
Tremblay et al., 2002). Given the important roles of calcineurin/
NFAT in immune cells, impaired anti-tumor immunity is conceiv-
ably the main culprit leading to the development of cancers in
transplant recipients. In addition, our data argue that the loss
of endothelial calcineurin/NFAT signaling directly contributes to
the progression of at least some cancer types because of the
loss of paracrine inhibitory communication between endothelial
and cancer cells.
In conclusion, we demonstrate the role of calcineurin in the
postnatal vasculature using an inducible endothelial-specific
deletion model. In both physiological retinal and pathological
tumor vasculatures, calcineurin is dispensable for sprouting
angiogenesis and is mostly implicated in vessel stabilization,
which does not affect primary tumor growth. EC calcineurin acti-
vation restrains the outgrowth of metastases, suggesting that
post-transplantation immunosuppressive therapy also directly
targets the endothelium, which is crucial for initial metastasis
formation, and is independent of immune cells.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILSer o
0 inj
njec
(F)B Animal models
B Cell culture
d METHOD DETAILS
B Tumor models
B Protein extraction and immunoblottingf CD31, collagen IV+ areas was normalized to the total vascularized area;
ection.
tion. *p = 0.0113, n = 13 Bmp2WT; n = 10 Bmp2Dbec. Data combined from 3
, (H–J), and (L). Scale bars: (E) 100 mm, (G) 500 mm, (K) 1 mm.
B Plasmids and transfections
B 2D Proliferation analysis
B Spheroid formation
B Retina preparation
B Cell staining
B Immunofluorescent and histochemical staining
B qRT-PCR
B RNA-sequencing
B Endothelial cell sorting
B Immune cell analysis
d QUANTIFICATION AND STATISTICAL ANALYSIS
B Image analysis
B Statistical analysis
B Public dataset analysis
B RNA-seq analysis
d DATA AND SOFTWARE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and two tables and can be
found with this article online at https://doi.org/10.1016/j.celrep.2019.01.016.
ACKNOWLEDGMENTS
We thank J. Schlom and L. Borsig for providing MC38 and MC38-GFP cells, M.
Fruttiger for Pdgfb-iCreERT2 mice, P. Scheiffele for Bmp2flox/flox mice, C. Beau-
verd for mouse genotyping and colonymaintenance, S. Ragusa for participating
in the initial stages of the project, and J. Bernier-Latmani for helpwith endothelial
cell isolation. Animal, Cellular Imaging, Flow Cytometry, Mouse Pathology and
Genomic Technology Facilities of the University of Lausanne are gratefully
acknowledged. This work was supported by the People Programme (Marie
Curie Actions) of the European Union’s Seventh Framework Programme FP7/
2007-2013/ under REA grant agreement 317250, the Swiss League for Cancer
Research (KLS-3406-02-2014), the Medic Foundation, the Novartis Foundation,
the EmmaMuschamp Foundation, the Fondation pour la Lutte Contre la Cancer
(to T.V.P.), the Joseph and Lina Spicher Foundation (to S.H. and L.W.), the
Novartis Foundation and Fondation Pierre Mercier (to A.S.), and the Alfred und
Anneliese Sutter-Sto¨ttner Stiftung and Fondation Nuovo-Soldati (to L.W.).
C.A.F. is supported by the European Research Council Starting Grant (679368).
AUTHOR CONTRIBUTIONS
S.H., S.C., and T.V.P. designed the study. S.H. performed the experiments,
analyzed and interpreted the data, and wrote the manuscript. S.C., B.P.-L.,
and L.W. performed the experiments and analyzed and interpreted the data.
A.S., C.F., and H.G. performed the experiments and analyzed the data. N.Z.,
S.N., and M.D. performed the bioinformatics analysis. T.V.P. directed the
study, interpreted the data, and wrote the manuscript. All of the authors
revised the manuscript critically.
DECLARATION OF INTERESTS
T.V.P. received a research grant from Hoffmann-La Roche to investigate
angiogenesis inhibitors.
Received: March 6, 2018
Revised: November 22, 2018
Accepted: January 4, 2019
Published: January 29, 2019
REFERENCES
Amiri, K.I., and Richmond, A. (2005). Role of nuclear factor-k B in melanoma.
Cancer Metastasis Rev. 24, 301–313.Armulik, A., Genove´, G., and Betsholtz, C. (2011). Pericytes: developmental,
physiological, and pathological perspectives, problems, and promises. Dev.
Cell 21, 193–215.
Baek, K.-H., Zaslavsky, A., Lynch, R.C., Britt, C., Okada, Y., Siarey, R.J.,
Lensch, M.W., Park, I.-H., Yoon, S.S., Minami, T., et al. (2009). Down’s syn-
drome suppression of tumour growth and the role of the calcineurin inhibitor
DSCR1. Nature 459, 1126–1130.
Baluk, P., Morikawa, S., Haskell, A., Mancuso,M., andMcDonald, D.M. (2003).
Abnormalities of basement membrane on blood vessels and endothelial
sprouts in tumors. Am. J. Pathol. 163, 1801–1815.
Bernier-Latmani, J., Cisarovsky, C., Demir, C.S., Bruand, M., Jaquet, M., Da-
vanture, S., Ragusa, S., Siegert, S., Dormond, O., Benedito, R., et al. (2015).
DLL4 promotes continuous adult intestinal lacteal regeneration and dietary
fat transport. J. Clin. Invest. 125, 4572–4586.
Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal
probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525–527.
Bushdid, P.B., Osinska, H., Waclaw, R.R., Molkentin, J.D., and Yutzey, K.E.
(2003). NFATc3 and NFATc4 are required for cardiac development and mito-
chondrial function. Circ. Res. 92, 1305–1313.
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A.,
Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio can-
cer genomics portal: an open platform for exploring multidimensional cancer
genomics data. Cancer Discov. 2, 401–404.
Chapman, J.R., Webster, A.C., and Wong, G. (2013). Cancer in the transplant
recipient. Cold Spring Harb. Perspect. Med. 3, a015677.
Chen, T., Wang, H., Liu, Y., Zhao, B., Zhao, Y., Fan, R., Wang, P., and Dong, C.
(2016). Ocular Albinism Type 1 Regulates Melanogenesis in Mouse Melano-
cytes. Int. J. Mol. Sci. 17, E1596.
Claxton, S., Kostourou, V., Jadeja, S., Chambon, P., Hodivala-Dilke, K., and
Fruttiger, M. (2008). Efficient, inducible Cre-recombinase activation in vascular
endothelium. Genesis 46, 74–80.
Courtwright, A., Siamakpour-Reihani, S., Arbiser, J.L., Banet, N., Hilliard, E.,
Fried, L., Livasy, C., Ketelsen, D., Nepal, D.B., Perou, C.M., et al. (2009).
Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/
NFAT signaling pathway. Cancer Res. 69, 4621–4628.
De, A. (2011). Wnt/Ca2+ signaling pathway: a brief overview. Acta Biochim.
Biophys. Sin. (Shanghai) 43, 745–756.
de la Pompa, J.L., Timmerman, L.A., Takimoto, H., Yoshida, H., Elia, A.J.,
Samper, E., Potter, J., Wakeham, A., Marengere, L., Langille, B.L., et al.
(1998). Role of the NF-ATc transcription factor in morphogenesis of cardiac
valves and septum. Nature 392, 182–186.
De Palma, M., Biziato, D., and Petrova, T.V. (2017). Microenvironmental regu-
lation of tumour angiogenesis. Nat. Rev. Cancer 17, 457–474.
Durinck, S., Moreau, Y., Kasprzyk, A., Davis, S., De Moor, B., Brazma, A., and
Huber, W. (2005). BioMart and Bioconductor: a powerful link between biolog-
ical databases and microarray data analysis. Bioinformatics 21, 3439–3440.
Durinck, S., Spellman, P.T., Birney, E., and Huber, W. (2009). Mapping identi-
fiers for the integration of genomic datasets with the R/Bioconductor package
biomaRt. Nat. Protoc. 4, 1184–1191.
Ferna´ndez-Barral, A., Orgaz, J.L., Baquero, P., Ali, Z., Moreno, A., Tiana, M.,
Go´mez, V., Riveiro-Falkenbach, E., Can˜adas, C., Zazo, S., et al. (2014). Reg-
ulatory and functional connection of microphthalmia-associated transcription
factor and anti-metastatic pigment epithelium derived factor in melanoma.
Neoplasia 16, 529–542.
Franco, C.A., Jones, M.L., Bernabeu, M.O., Geudens, I., Mathivet, T., Rosa, A.,
Lopes, F.M., Lima, A.P., Ragab, A., Collins, R.T., et al. (2015). Dynamic endo-
thelial cell rearrangements drive developmental vessel regression. PLoS Biol.
13, e1002125.
Franco, C.A., Jones,M.L., Bernabeu,M.O., Vion, A.-C., Barbacena, P., Fan, J.,
Mathivet, T., Fonseca, C.G., Ragab, A., Yamaguchi, T.P., et al. (2016). Non-
canonical Wnt signalling modulates the endothelial shear stress flow sensor
in vascular remodelling. eLife 5, e07727.Cell Reports 26, 1227–1241, January 29, 2019 1239
Fruttiger, M. (2007). Development of the retinal vasculature. Angiogenesis 10,
77–88.
Gao, H., Chakraborty, G., Lee-Lim, A.P., Mo, Q., Decker, M., Vonica, A., Shen,
R., Brogi, E., Brivanlou, A.H., and Giancotti, F.G. (2012). The BMP inhibitor
Coco reactivates breast cancer cells at lung metastatic sites. Cell 150,
764–779.
Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun,
Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of
complex cancer genomics and clinical profiles using the cBioPortal. Sci.
Signal. 6, pl1.
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abrams-
son, A., Jeltsch, M., Mitchell, C., Alitalo, K., Shima, D., and Betsholtz, C. (2003).
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell
Biol. 161, 1163–1177.
Graupera, M., Guillermet-Guibert, J., Foukas, L.C., Phng, L.-K., Cain, R.J.,
Salpekar, A., Pearce,W.,Meek, S., Millan, J., Cutillas, P.R., et al. (2008). Angio-
genesis selectively requires the p110alpha isoform of PI3K to control endothe-
lial cell migration. Nature 453, 662–666.
Gray, E.E., Friend, S., Suzuki, K., Phan, T.G., and Cyster, J.G. (2012). Subcap-
sular sinus macrophage fragmentation and CD169+ bleb acquisition by
closely associated IL-17-committed innate-like lymphocytes. PLoS One 7,
e38258.
Hao, J., Ho, J.N., Lewis, J.A., Karim, K.A., Daniels, R.N., Gentry, P.R., Hopkins,
C.R., Lindsley, C.W., and Hong, C.C. (2010). In vivo structure-activity relation-
ship study of dorsomorphin analogues identifies selective VEGF and BMP in-
hibitors. ACS Chem. Biol. 5, 245–253.
Herna´ndez, G.L., Volpert, O.V., In˜iguez, M.A., Lorenzo, E., Martı´nez-Martı´nez,
S., Grau, R., Fresno, M., and Redondo, J.M. (2001). Selective inhibition of
vascular endothelial growth factor-mediated angiogenesis by cyclosporin A:
roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp.
Med. 193, 607–620.
Jurisic, G., Maby-El Hajjami, H., Karaman, S., Ochsenbein, A.M., Alitalo, A.,
Siddiqui, S.S., Ochoa Pereira, C., Petrova, T.V., and Detmar, M. (2012).
An unexpected role of semaphorin3a-neuropilin-1 signaling in lymphatic
vessel maturation and valve formation. Circ. Res. 111, 426–436.
Kerr, B.A., West, X.Z., Kim, Y.-W., Zhao, Y., Tischenko, M., Cull, R.M., Phares,
T.W., Peng, X.-D., Bernier-Latmani, J., Petrova, T.V., et al. (2016). Stability and
function of adult vasculature is sustained by Akt/Jagged1 signalling axis in
endothelium. Nat. Commun. 7, 10960.
Kitamura, T., Qian, B.-Z., and Pollard, J.W. (2015). Immune cell promotion of
metastasis. Nat. Rev. Immunol. 15, 73–86.
Koch, P.-S., Olsavszky, V., Ulbrich, F., Sticht, C., Demory, A., Leibing, T.,
Henzler, T., Meyer, M., Zierow, J., Schneider, S., et al. (2016). Angiocrine
Bmp2 signaling in murine liver controls normal iron homeostasis. Blood 129,
415–419.
Kondo, T., and Hearing, V.J. (2011). Update on the regulation of mammalian
melanocyte function and skin pigmentation. Expert. Rev. Dermatol. 6, 97–108.
Korn, C., and Augustin, H.G. (2015). Mechanisms of Vessel Pruning and
Regression. Dev. Cell 34, 5–17.
Korn, C., Scholz, B., Hu, J., Srivastava, K., Wojtarowicz, J., Arnsperger, T.,
Adams, R.H., Boutros, M., Augustin, H.G., and Augustin, I. (2014). Endothelial
cell-derived non-canonical Wnt ligands control vascular pruning in angiogen-
esis. Development 141, 1757–1766.
Lanza, B., Ragnelli, A.M., Priore, M., and Aimola, P. (2017). Morphological and
histochemical investigation of the response of Olea europaea leaves to fungal
attack by Spilocaea oleagina. Plant Pathol. 66, 1239–1247.
Liberzon, A., Birger, C., Thorvaldsdo´ttir, H., Ghandi, M., Mesirov, J.P., and
Tamayo, P. (2015). The Molecular Signatures Database (MSigDB) hallmark
gene set collection. Cell Syst. 1, 417–425.
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
Ma, L., and Martin, J.F. (2005). Generation of a Bmp2 conditional null allele.
Genesis 42, 203–206.1240 Cell Reports 26, 1227–1241, January 29, 2019Mancini, M., and Toker, A. (2009). NFAT proteins: emerging roles in cancer
progression. Nat. Rev. Cancer 9, 810–820.
Medyouf, H., Alcalde, H., Berthier, C., Guillemin, M.C., dos Santos, N.R.,
Janin, A., Decaudin, D., de The´, H., and Ghysdael, J. (2007). Targeting
calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic
leukemia. Nat. Med. 13, 736–741.
Mena, M.-P., Papiewska-Pajak, I., Przygodzka, P., Kozaczuk, A., Boncela, J.,
and Cierniewski, C.S. (2014). NFAT2 regulates COX-2 expression and modu-
lates the integrin repertoire in endothelial cells at the crossroads of angiogen-
esis and inflammation. Exp. Cell Res. 324, 124–136.
Minami, T., Horiuchi, K., Miura, M., Abid, M.R., Takabe, W., Noguchi, N.,
Kohro, T., Ge, X., Aburatani, H., Hamakubo, T., et al. (2004). Vascular endothe-
lial growth factor- and thrombin-induced termination factor, Down syndrome
critical region-1, attenuates endothelial cell proliferation and angiogenesis.
J. Biol. Chem. 279, 50537–50554.
Minami, T., Jiang, S., Schadler, K., Suehiro, J., Osawa, T., Oike, Y., Miura, M.,
Naito, M., Kodama, T., and Ryeom, S. (2013). The calcineurin-NFAT-angio-
poietin-2 signaling axis in lung endothelium is critical for the establishment
of lung metastases. Cell Rep. 4, 709–723.
Monticelli, S., and Rao, A. (2002). NFAT1 and NFAT2 are positive regulators of
IL-4 gene transcription. Eur. J. Immunol. 32, 2971–2978.
Norrme´n, C., Ivanov, K.I., Cheng, J., Zangger, N., Delorenzi, M., Jaquet, M.,
Miura, N., Puolakkainen, P., Horsley, V., Hu, J., et al. (2009). FOXC2 controls
formation and maturation of lymphatic collecting vessels through cooperation
with NFATc1. J. Cell Biol. 185, 439–457.
Ryeom, S., Baek, K.-H., Rioth, M.J., Lynch, R.C., Zaslavsky, A., Birsner, A.,
Yoon, S.S., and McKeon, F. (2008). Targeted deletion of the calcineurin inhib-
itor DSCR1 suppresses tumor growth. Cancer Cell 13, 420–431.
Sabine, A., Agalarov, Y., Maby-El Hajjami, H., Jaquet, M., Ha¨gerling, R.,
Pollmann, C., Bebber, D., Pfenniger, A., Miura, N., Dormond, O., et al.
(2012). Mechanotransduction, PROX1, and FOXC2 cooperate to control
connexin37 and calcineurin during lymphatic-valve formation. Dev. Cell 22,
430–445.
Scholz, B., Korn, C., Wojtarowicz, J., Mogler, C., Augustin, I., Boutros, M.,
Niehrs, C., and Augustin, H.G. (2016). Endothelial RSPO3 Controls Vascular
Stability and Pruning through Non-canonical WNT/Ca(2+)/NFAT Signaling.
Dev. Cell 36, 79–93.
Schweighofer, B., Testori, J., Sturtzel, C., Sattler, S., Mayer, H., Wagner, O.,
Bilban, M., and Hofer, E. (2009). The VEGF-induced transcriptional response
comprises gene clusters at the crossroad of angiogenesis and inflammation.
Thromb. Haemost. 102, 544–554.
Sergushichev, A. (2016). An algorithm for fast preranked gene set enrichment
analysis using cumulative statistic calculation. bioRxiv. https://doi.org/10.
1101/060012.
Sherston, S.N., Carroll, R.P., Harden, P.N., and Wood, K.J. (2014). Predictors
of cancer risk in the long-term solid-organ transplant recipient. Transplantation
97, 605–611.
Soneson, C., Love, M.I., and Robinson, M.D. (2015). Differential analyses
for RNA-seq: transcript-level estimates improve gene-level inferences.
F1000Res. 4, 1521.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,
Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., andMe-
sirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach
for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA
102, 15545–15550.
Suehiro, J., Kanki, Y., Makihara, C., Schadler, K., Miura, M., Manabe, Y., Abur-
atani, H., Kodama, T., andMinami, T. (2014). Genome-wide approaches reveal
functional vascular endothelial growth factor (VEGF)-inducible nuclear factor
of activated T cells (NFAT) c1 binding to angiogenesis-related genes in the
endothelium. J. Biol. Chem. 289, 29044–29059.
Tremblay, F., Fernandes, M., Habbab, F., deB Edwardes, M.D., Loertscher,
R., and Meterissian, S. (2002). Malignancy after renal transplantation:
incidence and role of type of immunosuppression. Ann. Surg. Oncol. 9,
785–788.
Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K.M., Lay, J., Wong, D.J.L.,
Atefi, M., Shirazi, R., Wang, X., et al. (2018). Multi-stage Differentiation Defines
Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-
Dependent Oxidative Stress. Cancer Cell 33, 890–904.e5.
Vigl, B., Aebischer, D., Nitschke´, M., Iolyeva, M., Ro¨thlin, T., Antsiferova, O.,
and Halin, C. (2011). Tissue inflammation modulates gene expression of
lymphatic endothelial cells and dendritic cell migration in a stimulus-depen-
dent manner. Blood 118, 205–215.Zaichuk, T.A., Shroff, E.H., Emmanuel, R., Filleur, S., Nelius, T., and Volpert,
O.V. (2004). Nuclear factor of activated T cells balances angiogenesis activa-
tion and inhibition. J. Exp. Med. 199, 1513–1522.
Zeini, M., Hang, C.T., Lehrer-Graiwer, J., Dao, T., Zhou, B., and Chang, C.-P.
(2009). Spatial and temporal regulation of coronary vessel formation by calci-
neurin-NFAT signaling. Development 136, 3335–3345.
Zeng, H., Chattarji, S., Barbarosie, M., Rondi-Reig, L., Philpot, B.D., Miya-
kawa, T., Bear, M.F., and Tonegawa, S. (2001). Forebrain-specific calcineurin
knockout selectively impairs bidirectional synaptic plasticity and working/
episodic-like memory. Cell 107, 617–629.Cell Reports 26, 1227–1241, January 29, 2019 1241
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit anti-GAPDH Sigma RRID:AB_796208
Rabbit anti-P-Smad-1/5 Cell Signaling RRID:AB_491015
Rabbit anti-Smad1 Cell Signaling RRID:AB_10858882
Mouse anti-NFATc1 BD Bioscience RRID:AB_396478
Rat anti-CD45-PeCy7 eBioscience RRID:AB_2716950
Rat anti-CD31-Pe eBioscience RRID:AB_465631
Gp38-AlexaFluor647 In house Clone 8.1.1
Rat anti.EpCAM-eFluor450 Biolegend RRID:AB_10717090
Rat anti-CD31/PECAM-1 BD Bioscience RRID:AB_396660
Rabbit anti-collagen IV Millipore RRID:AB_2276457
Goat anti-CD13/Anpep R&D systems RRID:AB_2227288
Rat anti-Icam2 BD Bioscience RRID:AB_394784
Rabbit anti-cleaved caspase-3 Cell Signaling RRID:AB_2341188
Rabbit anti-Erg1/2/3 Santa Cruz RRID:AB_675518
Goat anti-Vegfr2 R&D systems RRID:AB_355500
Rat anti-GFP Biolegend RRID:AB_1279414
Rabbit anti-NG2 Millipore RRID:AB_91789
Rat anti-CD144 BD Bioscience RRID:AB_395707
Rat anti-CD45-FITC BD Bioscience RRID:AB_394610
Rat anti-CD3ε-e660 Biolegend RRID:AB_492861
Rat anti-CD8a-PerCP-Cy5.5 Biolegend RRID:AB_2075239
Rat anti-CD4-Alexa Fluor 700 Biolegend RRID:AB_493701
Rat anti-CD44-Pe-Cy7 Biolegend RRID:AB_830787
Rat anti-CD62L-Pe Biolegend RRID:AB_2270062
Rat anti-B220-Texas Red Thermo Fisher RRID:AB_10372805
Rat anti-CD11b-eFluor780 Thermo Fisher RRID:AB_1603193
Rat anti-Gr1-Alexa647 Biolegend RRID:AB_389331
Rat anti-Ly6C-PerCP-Cy5.5 Biolegend RRID:AB_1659241
Rat anti-NK1.1-PEe Biolegend RRID:AB_313395
Chemicals, Peptides, and Recombinant Proteins
DMH1 Tocris Cat#4126
Recombinant human/mouse/rat-BMP2 R&D Cat#355-BM
Tamoxifen Sigma Cat#T5648
EdU Santa Cruz Cat#sc-284628
Matrigel Corning Cat#356231
Luciferin Biosynth Cat#L-8220
Collagenase A Roche Cat#10103586001
Collagenase type IV Worthington Cat#LS004188
DNaseI Sigma Cat#11284932001
Fluoromount-G eBioscience Cat#00-4959-52
L-3,4-dihydroxyphenylalanine Sigma Cat#59-92-7
7AAD eBioscience Cat#00-6993-50
FITC-IB4 Invitrogen Cat#I-32450
(Continued on next page)
e1 Cell Reports 26, 1227–1241.e1–e6, January 29, 2019
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
EGM-2 Endothelial Cell Growth Medium-2 BulletKit Lonza Cat#3162
CellTracker Orange CMTMR Dye Invitrogen Cat#C2927
Critical Commercial Assays
CyQUANT NF Cell Proliferation Assay Kit Invitrogen Cat#C35006
RNA isolation RNeasy plus mini/micro kit QIAGEN Cat#74134/ Cat#74034
Transcriptor First strand cDNA synthesis kit Roche Cat#04896866001
SYBRGreen PCR Master mix Kapa Biosystems/ Bioline Cat#kk4605/ Cat#BIO-92005
Ovation RNA-seq system V2 Nugen Cat#7102
Illumina TruSeq Stranded mRNA reagents Illumina Cat#20020594
Illumina TruSeq SR Cluster Kit v4 Illumina Cat#GD-401-4001
Deposited Data
RNaseq B16F10 spheroids Vehicle versus Bmp2 treated This paper GEO: GSE117074
Experimental Models: Cell Lines
HUVECs, polled donor Lonza Cat#C2519A
B16F10-luciferase Perkin Elmer CVCL_5J39
B16F10-GFP This paper N/A
MC38 Lab of Jeffrey Schlom N/A
MC38-GFP Lab or Lubor Borsig N/A
HEK293T ATCC Cat#CRL-3216
Experimental Models: Organisms/Strains
Mouse: Cnb1flox/flox (C57BL/6-Ppp3r1tm1Stl/J) The Jackson Laboratory JAX: 006581
Mouse: Tg(Pdgfb-icre/ERT2)1Frut Lab of Marcus Fruttiger RRID:MGI:5284856
Mouse: B6;129S4-Bmp2 < tm1Jfm > /J Lab of Peter Scheiffle JAX: 016230
Oligonucleotides
Please see Table S2 This paper N/A
Software and Algorithms
Fiji NIH RRID:SCR_002285
Prism version 7 Graphpad RRID:SCR_002798
Living Image Software PerkinElmer RRID:SCR_014247
Imaris Bitplane RRID:SCR_007370
bcl2fastq Conversion Software Illumina RRID:SCR_015058
Other
caNFATc1 plasmid Addgene #11102CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the Lead Contact, Tatiana V.
Petrova (Tatiana.petrova@unil.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal models
Experiments were approved by the Animal Ethics Committee of the Canton of Vaud. Ppp3r1fl/fl, BMP2fl/fl and Pdgfb-iCreERT2 mice
(Claxton et al., 2008;Ma andMartin, 2005; Zeng et al., 2001) were onC57Bl6J background. Adult (5 – 10weeks old) femalemicewere
injected i.p. with 50 mg/g mouse of tamoxifen in sunflower seed oil (Sigma). Unless indicated otherwise, tamoxifen was administered
on day 2 and 0 of cancer cell injection and twice weekly thereafter. Deletion efficiency was confirmed by qRT-PCR of sorted lung
and tumor ECs. Pups were injected at P1 and P3 with 20 ml of 2 mg/ml tamoxifen.Cell Reports 26, 1227–1241.e1–e6, January 29, 2019 e2
Cell culture
Cells were cultured in a sterile incubator at 37C and 5%CO2. HUVECs (pooled donor, Lonza) were cultured in endothelial growth
medium with full supplements (EBM-2, Lonza) and were used up to passage 6. MC38, B16F10-luc and 293T were cultured in
DMEM complete (10% FBS, 1% P/S), for B16F10-luc cells zeocin 0.2 mg/ml was added to the culture medium.
METHOD DETAILS
Tumor models
For subcutaneous tumor experiments 5x105 B16F10-luc cells (B16F10-luc-G5, Perkin Elmer) in 100 ml PBS were injected in the right
flank of the mice. When tumors reached 1 cm3 mice were sacrificed and perfused intracardially with PBS and 2% PFA. 1 hour prior
to sacrifice mice were injected i.p. with 5 mg/g EdU (Life Technologies). Tumors were fixed in 4% PFA for 4h at 4C, incubated for
12 hours in 30% sucrose and embedded in OCT. For the lung colonization experiments 5x105 B16F10-luciferase cells in 200 ml
PBS were injected into tail vein, mice were sacrificed after 1, 5, 12 and 19 days and perfused intracardially with PBS and 2%
PFA. Lungs were fixed in 4% PFA for 4 hours, left in 30% sucrose for 12 hours, OCT inflated via the trachea and embedded in
OCT. In outgrowth experiments the first dose of tamoxifen was administered 5 or 9 days after cancer cell injection, and every
two days thereafter. For the 24h tumor cell extravasation assay B16F10-luc were labeled with 15 mm CMTMR (Thermo Fisher) by
incubating for 1h at 37C in serum free medium.
Protein extraction and immunoblotting
Cells were lysed in RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% sodium
dodecyl sulfate) supplemented with phosphatase (PhosSTOP, Roche) and protease (Complete, Roche) inhibitors. Lysates were
cleared by centrifugation and supernatants were loaded on 10% SDS-PAGE gels, transferred on nitrocellulose membranes and
blocked for 1h at RT in 5%BSA.Membraneswere incubated overnight at 4Cwith primary antibodies and for 1h at RTwith secondary
antibodies conjugated to horseradish peroxidase (Dako). Blots were developed using Super Signal West Femto (Thermo Scientific)
with a CCD camera (Fusion, Vilber). Details of the antibodies used are provided in the Key Resources Table.
Plasmids and transfections
caNFATc1 construct Addgene plasmid #11102 was subcloned into the pSD44 lentiviral backbone. pSD44-GFP was used as control.
Lentiviral particles were prepared by transfecting HEK293T cells with the pSD44 vector of interest and packaging plasmids pSD11
and pSD16. 48h after transfection supernatants were collected and concentrated. For infection 3.5x105 HUVECs were plated in a
10cm dish and infected the day after in the presence of polybrene (8 mg/ml) with either GFP or caNFATc1 lentiviruses. The medium
was changed 24h later and another 24h later cells were selected with 0.5 mg/ml puromycine for 48 hours.
For the generation of the B16F10-GFP cell line B16F10 were seeded in a 6 well plate and infected the day after with GFP lentivirus.
48h after transfection selection was started with 0.6 mg/ml puromycine, which remained in the culture medium. Single clones were
selected to choose cells with the brightest GFP signal.
2D Proliferation analysis
For analysis of cell growth, cells were seeded in 96 well plates at a density of 1000 cells/well, 100 ng/ml rBMP2 (R&D) or vehicle
treatment was added for 24 or 48 hours. Live cell number was determined using CyQuant NF DNA-based assay (Invitrogen).
Spheroid formation
500 B16F10 or 300MC38 cells were plated in 50 ml of 7 mg/ml Matrigel (Corning) and cultured for approximately 10 days, depending
on the experiment. 100 ng/ml of mouse rBMP2 (R&D) was added in the presence or absence of 3 mM DMH1 (Tocris) in DMEM
complete medium and was changed every other day. At the end of the experiment, the whole well was imaged with a Leica
M205FA stereomicroscope, using Leica camera DFC300FXR2 and LAS AF6000 software. For quantification, 3 images per well
were taken with a Leica DMI3000 microscope, using a DFC3000G camera and LAS X software. B16F10-luc spheroids were imaged
with the Xenogen IVIS Lumina II system after supplementation with 0.3 mg/ml luciferin (Biosynth) and analysis was performed with
Living Image software (Perkin Elmer).
Retina preparation
Pups were injected at P1 and P3 with 20 ml of 2 mg/ml tamoxifen in sunflower seed oil. Pups were sacrificed at day 5 and eyeballs
were fixed in 4% PFA for 4 hours at 4C. Retinas were dissected and blocked with blocking buffer (0.5% BSA, 5% donkey serum,
0.3% Triton X-100, 0.1% NaN3) for 6h at 4
C. Primary antibodies were diluted in blocking buffer and incubated overnight at 4C.
Subsequently, retinas were incubated with fluorophore-conjugated Alexa secondary antibodies (Thermo Fisher) in blocking buffer
overnight at 4C and mounted with mounting medium (Fluoromount-G, Invitrogen). Details of the antibodies used are provided in
the Key Resources Table.e3 Cell Reports 26, 1227–1241.e1–e6, January 29, 2019
Cell staining
Cells were grown on glass coverslips, washed once with cold PBS (with calcium chloride and magnesium chloride), fixed for
10 minutes in 4% PFA in PBS, permeabilized for 10 minutes with 0.1% Triton X-100 in PBS, blocked for 30 minutes with blocking
buffer (0.5% BSA, 5% donkey serum, 0.3% Triton X-100, 0.1% NaN3) and incubated with primary antibodies for 1h at RT. Cells
were then washed 3 3 10 minutes with 0.1% Triton-x PBS and incubated with fluorophore-conjugated Alexa secondary antibodies
(Thermo Fisher) in blocking buffer for 1h at RT, washed again for 3 3 10 minutes with 0.1% Triton-x PBS and once with PBS before
mountingwithmountingmedium (Fluoromount-G, Invitrogen). Details of the antibodies used are provided in the Key Resources Table
Immunofluorescent and histochemical staining
8 mm OCT sections were thawed for 20 minutes at RT, fixed for 10 minutes in 4% PFA and washed with 0.3% Triton-x PBS. After
blocking for 30 minutes with blocking buffer (0.5% BSA, 5% donkey serum, 0.3% Triton X-100, 0.1% NaN3) slides were incubated
with primary antibodies overnight at 4C in blocking buffer. On day 2, slides were washed 3 x with 0.3% Triton-x PBS for 10 minutes
and fluorophore-conjugated Alexa secondary antibodies (Thermo Fisher) were added in blocking buffer for 1h at RT. Slides were
washed 3 3 10 minutes with 0.3% Triton-x PBS and once with PBS before mounting.
For the analysis of tyrosinase activity lung cryostat sections were incubated with 5 mM of L-3,4-dihydroxyphenylalanine (L-DOPA,
Sigma-Aldrich) in 0.1 mM sodium phosphate buffer at pH 7.4 for 2 h at 37C; controls were incubated with the buffer alone. The
sections were fixed in 4% PFA for 15 min at RT, counterstained with Mayer’s hematoxilin and mounted.
qRT-PCR
RNA was isolated using the QIAGEN RNeasy Plus Mini Kit. Reverse transcription was performed using Transcriptor First Strand
cDNA Synthesis Kit (Roche). Alternatively, RNA from FACS samples was isolated using the QIAGEN RNeasy Plus Micro Kit and
mRNA was amplified using the Ovation RNA-seq system V2 (Nugen). StepOnePlus (Applied Biosystems) and SYBR Green PCR
Master Mix (Kapa Biosystems/Bioline) were used for qRT-PCR analyses. Data was normalized to GAPDH (HUVECs) or B2m
(FACS samples) using the comparative Ct (DDCt) method. Sequences of PCR primers are provided in Table S2.
RNA-sequencing
RNA quality was assessed on a Fragment Analyzer (Advanced Analytical Technologies, Inc., Ankeny, IA, USA) and all RNAs had a
RQN between 9.4 and 10.
RNA-seq libraries were prepared using 500 ng of total RNA and the Illumina TruSeq StrandedmRNA reagents (Illumina; San Diego,
California, USA). Cluster generation was performed with the resulting libraries using the Illumina TruSeq SR Cluster Kit v4 reagents
and sequenced on the Illumina HiSeq 2500. Sequencing data were demultiplexed using the bcl2fastq Conversion Software (v. 2.20,
Illumina; San Diego, California, USA).
Endothelial cell sorting
For sorting of endothelial cells we used the Pdgfb-iCreERT2tg/+ (Cnb1WT-GFP) as controls, which express EGFP in the Pdgfb-
iCreERT2 construct (Claxton et al., 2008)
For isolation of tumor endothelial cells Cnb1Dbec and Cnb1WT-GFP mice were injected s.c. with 5x105 B16F10-luc cells and
tamoxifen was administered. 7 days after cancer cell injection mice were sacrificed. Following 30 min incubation with 10% collage-
nase type IV (Worthington) and 50 mg/ml DNaseI (Roche) in 0.1% BSA at 37C, the tumor digest was filtered through 100 mm and
40 mm cell strainers to obtain single cell suspension. Cell were stained with antibodies listed in the Key Resources Table. Endothelial
cells were selected as the CD45-GFP+CD31+ population.
Intestinal LECswere isolated from adult small intestine using cell sorting as described previously (Bernier-Latmani et al., 2015). The
intestine was dissected and flushed with ice-cold PBS. Peyer’s patches were removed and the intestine was cut into 1 cm pieces,
which were put in a 10 mM EDTA solution with agitation at 37C for 30 minutes to remove epithelial cells. The remaining tissue was
then digested with Collagenase IV (3 mg/ml) in complete DMEM (GIBCO; ThermoFisher Scientific) containing CaCl2 (2 mM) and
50 mg/ml DNase I, with constant stirring at 37C for 20 minutes and washed with medium. The cell suspension was incubated
with labeled antibodies listed in the Key Resources Table.
Skin endothelial cells were isolated frommouse ears as described previously (Vigl et al., 2011). Ears were separated into dorsal and
ventral halves, cut into small pieces and digested in PBS containing 10 mg/mL of collagenase IV, for 13 minutes at 37C while
continuously rotating. This mix was passed through a 70 mm cell strainer placed in a 6 well plate and tissues were minced for
4 minutes. The plate with strainers was placed back at 37C for 8 minutes. Cell suspension was placed on ice and passed another
4 times through a 40-mmcell strainer. Single-cell suspensions were stained with labeled antibodies listed in the Key Resources Table.
For isolation of lung endothelial cells Cnb1Dbec and Cnb1WT-GFP, mice were injected i.v. with 5x105 B16F10-luc cells and i.p. with
tamoxifen. 5 days after cancer cell injection, mice were anesthetized and perfused intracardially first with PBS and then with a
digestion mix of 0.1% collagenase A (Roche) and 50 mg/ml DNaseI (Roche) in 0.1% BSA. Lungs were cut in pieces and incubated
in digestion mix at 37C for 45 minutes while continuously rotating at 150 rpm. Digested tissue was filtered through 100 mm and
40 mm cell strainers to obtain single cell suspension. 20 million cells were stained with antibodies listed in the Key Resources Table.
All FACS sorting was performed on a BD FACSAria II (BD Bioscience).Cell Reports 26, 1227–1241.e1–e6, January 29, 2019 e4
Initially, we aimed to isolate lung BECs as Pdpn-CD31+GFP+ and lymphatic endothelial cells (LECs) as Pdpn+CD31+GFP- pop-
ulations. Unexpectedly, we identified a third major Pdpn+CD31+GFP+ endothelial cell population, which we refer to here as BEC-2
(Figure S6E). qRT-PCR analysis of BEC, BEC-2 and LEC populations demonstrated that all of them expressed the pan-endothelial
markers CD31 and VE-cadherin (Figure S6F). BEC and BEC-2 were furthermore enriched in the blood endothelial-specific marker
Vegfr1 (Jurisic et al., 2012) (Figure S6G). In contrast lymphatic markers Prox1, Vegfr3, Itga9, Nrp2 and Pdpn were highly expressed
in LECs (Figure S6H). BEC-2 population showed no expression of lymphatic markers and more strikingly, although the cells were
sorted based on the cell surface Pdpn+ expression, they did not contain Pdpn mRNA (Figure S6H). We thus propose that due
to the particular organization of the lung capillary vasculature, the endothelial cells, located in close proximity of the podoplanin-
expressing epithelial cells in order to allow gas exchange, acquire membrane of podoplanin positive cells during tissue digestion.
The phenomena of cell membrane transfer was described before in subcapsular sinus macrophages (Gray et al., 2012). However,
these cells that appear as Pdpn+ BECs (BEC-2) in our FACS analyses, will have not undergone any RNA transfer as they are devoid
of Pdpn mRNA.
Immune cell analysis
For immune cell analysis we used Cnb1WT and Cnb1Dbec animals injected with 5x105 B16F10-luc cells. 5 or 7 days after cancer cell
injection, mice were anesthetized and perfused intracardially with PBS. Lungs were cut in pieces and digested in digestion mix
(1mg/ml Collagenase type IV in DMEM) at 37C for 45 minutes while continuously rotating at 150 rpm. Digested tissue was filtered
through a 70 mm cell strainer to obtain single cell suspension. Cells were then stained for flow cytometry with anti-CD45-FITC, anti-
CD3ε-e660, anti-CD8a-PerCP-Cy5.5, anti-CD4-A700, anti-CD44-Pe-Cy7, anti-CD62L-Pe and anti-B220-Texas Red ( = lymphoid
panel) or with anti-CD45-FITC, anti-CD11b-eFluor780, anti-Gr1-Alexa647, anti-Ly6C-PerCP-Cy5.5, anti-NK1.1-Pee, and anti-
B220-Texas Red ( = innate immune cell panel). Data were acquired on LSR II (BD Bioscience) and analyzed using FlowJo software
(BD Bioscience). The following populations were analyzed: B cells (CD45+B220+), effector memory (CD62L-CD44+), central memory
(CD62L+CD44+) and naive (CD62L+CD44-) CD4+ and CD8+ T cells, monocytes (Cd11b+Ly6C+), natural killer (Cd11b+/NK1.1+) and
neutrophils (Cd11b+GR1hi).
QUANTIFICATION AND STATISTICAL ANALYSIS
Image analysis
Retinas were imagedwith an upright Zeiss Axio Imager Z1 using the tile scan and stitching function, for general overview pictures and
to quantify the vessel branching and radial expansion. For vessel regression pictures were obtained with an inverted Zeiss LSM 880
confocal microscope. Retina analysis was performed with the Fiji software. Vessel regression analysis was performed by counting
the collagen IV positive Icam2 negative structures and normalizing the counts to the total Icam2 positive area. Radial expansion was
measured as the distance between the vascular front and the central optic nerve. Arterial and venous vessel branching was counted
as the number of vessels branching off from the big central artery of vein visible per leaflet. Overall pericyte coverage was determined
by measuring the total CD13 stained surface, further collagen IV positive, CD31 negative areas were selected and checked for CD13
positive staining to observe pericytes in empty sleeves. Proliferation of endothelial cells was measured in regions containing the
vascular sprouting front by dividing the total number of ERG+ endothelial cell nuclei by the number of positive for ERG/EdU cells
in 3–5 20x objective images. Apoptosis was quantified as the number of cleaved caspase-3+ events in CD31+ vessels divided by
the total CD31 vessel area, and given as percentage of control.
For whole section analysis slides were imaged with the upright Zeiss Axio Imager Z1 using the tile scan and stitching function or
either with the slide scanner Axio Scan.Z1. Confocal images were captured with an inverted Zeiss LSM 880 microscope. Area mea-
surements were carried out using ImageJ software. Tumor vessel density was quantified as the CD31 area normalized to the total
DAPI tumoral area. Empty sleeves in primary tumors were defined as avascular, CD31 negative regions, that were positive for
collagen IV and 5 images per tumor were analyzed. For proliferation in lung metastasis, EdU was quantified as the total EdU positive
area normalized to the whole lung section area. For the experiment using B16F10-GFP cells, EdUwas normalized to the GFP positive
metastatic area.
Statistical analysis
Pairwise comparisons were performed by two-tailed Student’s t test. The MC38 3D spheroid growth in vitro and the mRNA
expression of LEC, BEC and BEC-2 for their specific markers was analyzed by two-way ANOVA. Statistical details of experiments
can be found in the figure legends.
Public dataset analysis
Affymetrix Human Genome U133 Plus 2.0 Array gene expression profiling dataset GSE49426 (Suehiro et al., 2014) from HUVECs
treated with 50ng/ml VEGFA in the presence or absence of 1mM Cyclosporin A or HUVECs with adenovirally overexpressed
caNFATc1 was downloaded and normalized with RMA (affy R package). Differential expression was computed with limma. In the
absence of replicates, cutoffs based on log fold change (LFC) were decided to define differentially expressed genes: LFC > 0.5
defined upregulation by VEGFA in the absence of Cyclosporin A, LFC > 0.5 defined upregulation by VEGFA in the presence ofe5 Cell Reports 26, 1227–1241.e1–e6, January 29, 2019
Cyclosporin A, LFC > 2.5 defined upregulation by caNFATc1. Genes induced by VEGFA without Cyclosporin A and induced by
caNFATc1, but not induced by VEGFA in the presence of Cyclosporin A were selected and their expression is shown in a heatmap.
RNA-seq analysis
Mouse target transcript sequences were obtained from ENSEMBLE (GRCm38.p6), and the abundances of transcripts were
quantified using Kallisto (0.44.0) with default parameters (Bray et al., 2016). Kallisto’s transcript-level estimates were then summa-
rized at the gene-level using tximport (1.8.0) from Bioconductor (Soneson et al., 2015). Raw and processed data are accessible from
Gene Expression Omnibus (GEO) under accession number GSE117074.
Differential expression analysis was performed using DESeq2 (1.20.0) from Bioconductor (Love et al., 2014), with FDR < 0.05
and FoldChange > 2 as significance criteria. For gene set enrichment analysis (GSEA), human orthologs of mouse genes were ob-
tained using biomaRt (2.36.1) (Durinck et al., 2005, 2009). GSEA enrichment scores were then computed using fgsea (1.6.0) from
Bioconductor (Sergushichev, 2016), with gene sets obtained from MSigDB database (Liberzon et al., 2015; Subramanian et al.,
2005), and DESeq20s LOG2FC as gene ranking metric.
We defined the Bmp2-treated mouse melanoma signature as the aggregated list of up- and downregulated genes obtained from
DESeq2. To compare the enrichment of the Bmp2-treated mouse melanoma signature across human melanoma subtypes,
processed gene expression data of metastatic skin cutaneous melanoma (SKCM) from TCGA was obtained from the cBioPortal
(Cerami et al., 2012; Gao et al., 2013). Expression data was log transformed with offset = 1, and standardized across samples.
Sample labels assigning each tumor to one of the four differentiation subtypes (melanocytic, transitory, neural crest-like, and
undifferentiated) were directly obtained from (Tsoi et al., 2018). An enrichment score was then computed for the Bmp2-
treated mouse melanoma signature per tumor, using a weighted sum of standardized expression values, where the weight was
set to +1 for upregulated genes and 1 for downregulated genes.
DATA AND SOFTWARE AVAILABILITY
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